

Date Collected: 01/20/2025

Date Received: 01/21/2025

Date Reported: 01/30/2025

Fasting: Yes

Ordered Items: **NMR LipoProfile+Lipids+IR; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Complete; OmegaCheck(TM) (EPA+DPA+DHA); Iron and TIBC; Testosterone Free, Profile I; Albumin/Creatinine Ratio,Urine; ABO Grouping and Rho(D) Typing; PSA Total (Reflex To Free); Hemoglobin A1c; Thyroxine (T4) Free, Direct; Folate (Folic Acid), Serum; DHEA-Sulfate; Cortisol; TSH; Luteinizing Hormone(LH); FSH; Prolactin; Estradiol; Rheumatoid Factor (RF); Lead, Blood (Adult); IGF-1; Vitamin D, 25-Hydroxy; Lipoprotein (a); C-Reactive Protein, Cardiac; Leptin, Serum; Homocyst(e)ine; Uric Acid; GGT; Amylase; Lipase; Vitamin B12; Magnesium; Zinc, Plasma or Serum; Insulin; Ferritin; Triiodothyronine (T3), Free; Apolipoprotein B; Venipuncture**

General Comments & Additional Information

Clinical Info: X03152

Date Collected: 01/20/2025

NMR LipoProfile+Lipids+IR

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LDL Particle Number ⁰¹				
LDL-P ^{A, 01}	830		nmol/L	<1000
		Low	< 1000	
		Moderate	1000 - 1299	
		Borderline-High	1300 - 1599	
		High	1600 - 2000	
		Very High	> 2000	
Lipids ⁰¹				
LDL-C (NIH Calc) ⁰¹	96		mg/dL	0-99
		Optimal	< 100	
		Above optimal	100 - 129	
		Borderline	130 - 159	
		High	160 - 189	
		Very high	> 189	
HDL-C ^{A, 01}	45		mg/dL	>39
Triglycerides ^{A, 01}	113		mg/dL	0-149
Cholesterol, Total ^{A, 01}	161		mg/dL	100-199
LDL and HDL Particles ⁰¹				
HDL-P (Total) ^{A, 01}	34.8		umol/L	>=30.5
Small LDL-P ^{A, 01}	207		nmol/L	<=527
LDL Size ^{A, 01}	21.1		nm	>20.5

** INTERPRETATIVE INFORMATION**					
PARTICLE CONCENTRATION AND SIZE					
<---Lower CVD Risk Higher CVD Risk-->					
LDL AND HDL PARTICLES	Percentile in	Reference Population			
HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
LDL Size	<-Large (Pattern A)->		<-Small (Pattern B)->		
	23.0	20.6	20.5	19.0	

Comment:⁰¹

Date Collected: 01/20/2025

NMR LipoProfile+Lipids+IR (Cont.)

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance/Diab. Risk ⁰¹			
Large VLDL-P ^{A, 01}	0.8		nmol/L <=2.7
Small LDL-P ^{A, 01}	207		nmol/L <=527
▼ Large HDL-P ^{A, 01}	3.5	Low	umol/L >=4.8
VLDL Size ^{A, 01}	40.1		nm <=46.6
LDL Size ^{A, 01}	21.1		nm >=20.8
▼ HDL Size ^{A, 01}	9.0	Low	nm >=9.2
Insulin Resistance Score ⁰¹			
LP-IR Score ^{A, 01}	27		<=45

INSULIN RESISTANCE / DIABETES RISK MARKERS					
<--Insulin Sensitive			Insulin Resistant-->		
Percentile in Reference Population					
Large VLDL-P	Low	25th	50th	75th	High
	<0.9	0.9	2.7	6.9	>6.9
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
Large HDL-P	High	75th	50th	25th	Low
	>7.3	7.3	4.8	3.1	<3.1
VLDL Size	Small	25th	50th	75th	Large
	<42.4	42.4	46.6	52.5	>52.5
LDL Size	Large	75th	50th	25th	Small
	>21.2	21.2	20.8	20.4	<20.4
HDL Size	Large	75th	50th	25th	Small
	>9.6	9.6	9.2	8.9	<8.9
Insulin Resistance Score					
LP-IR SCORE	Low	25th	50th	75th	High
	<27	27	45	63	>63

Comment: ⁰¹	LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.
------------------------	--

CBC With Differential/Platelet

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
WBC ⁰²	4.0		x10E3/uL	3.4-10.8
RBC ⁰²	4.92		x10E6/uL	4.14-5.80
Hemoglobin ⁰²	15.5		g/dL	13.0-17.7
Hematocrit ⁰²	45.9		%	37.5-51.0
MCV ⁰²	93		fL	79-97
MCH ⁰²	31.5		pg	26.6-33.0
MCHC ⁰²	33.8		g/dL	31.5-35.7
RDW ⁰²	11.8		%	11.6-15.4
Platelets ⁰²	152		x10E3/uL	150-450
Neutrophils ⁰²	49		%	Not Estab.

Date Collected: 01/20/2025

CBC With Differential/Platelet (Cont.)

Lymphs ⁰²	35	%	Not Estab.
Monocytes ⁰²	9	%	Not Estab.
Eos ⁰²	6	%	Not Estab.
Basos ⁰²	1	%	Not Estab.
Neutrophils (Absolute) ⁰²	2.0	x10E3/uL	1.4-7.0
Lymphs (Absolute) ⁰²	1.4	x10E3/uL	0.7-3.1
Monocytes(Absolute) ⁰²	0.4	x10E3/uL	0.1-0.9
Eos (Absolute) ⁰²	0.2	x10E3/uL	0.0-0.4
Baso (Absolute) ⁰²	0.0	x10E3/uL	0.0-0.2
Immature Granulocytes ⁰²	0	%	Not Estab.
Immature Grans (Abs) ⁰²	0.0	x10E3/uL	0.0-0.1

Comp. Metabolic Panel (14)

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
Glucose ⁰²	94			mg/dL	70-99
▲ BUN ⁰²	25	High		mg/dL	6-24
Creatinine ⁰²	1.04			mg/dL	0.76-1.27
eGFR	90			mL/min/1.73	>59
▲ BUN/Creatinine Ratio	24	High			9-20
Sodium ⁰²	143			mmol/L	134-144
Potassium ⁰²	4.4			mmol/L	3.5-5.2
Chloride ⁰²	104			mmol/L	96-106
Carbon Dioxide, Total ⁰²	20			mmol/L	20-29
Calcium ⁰²	9.5			mg/dL	8.7-10.2
Protein, Total ⁰²	7.1			g/dL	6.0-8.5
Albumin ⁰²	4.5			g/dL	4.1-5.1
Globulin, Total	2.6			g/dL	1.5-4.5
Bilirubin, Total ⁰²	0.3			mg/dL	0.0-1.2
Alkaline Phosphatase ⁰²	80			IU/L	44-121
AST (SGOT) ⁰²	31			IU/L	0-40
ALT (SGPT) ⁰²	19			IU/L	0-44

Urinalysis, Complete

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Urinalysis Gross Exam ⁰²				
Specific Gravity ⁰²	1.007			1.005-1.030
pH ⁰²	7.0			5.0-7.5
Urine-Color ⁰²	Yellow			Yellow
Appearance ⁰²	Clear			Clear
WBC Esterase ⁰²	Negative			Negative
Protein ⁰²	Negative			Negative/Trace
Glucose ⁰²	Negative			Negative
Ketones ⁰²	Negative			Negative
Occult Blood ⁰²	Negative			Negative

Date Collected: 01/20/2025

Urinalysis, Complete (Cont.)

Bilirubin ⁰²	Negative		Negative
Urobilinogen,Semi-Qn ⁰²	0.2	mg/dL	0.2-1.0
Nitrite, Urine ⁰²	Negative		Negative
Microscopic Examination ⁰²	Microscopic follows if indicated.		
Microscopic Examination ⁰²	See below: Microscopic was indicated and was performed.		
WBC ⁰²	None seen	/hpf	0-5
RBC ⁰²	None seen	/hpf	0-2
Epithelial Cells (non renal) ⁰²	None seen	/hpf	0-10
Casts ⁰²	None seen	/lpf	None seen
Bacteria ⁰²	None seen		None seen/Few

OmegaCheck(TM) (EPA+DPA+DHA)

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
▼ OmegaCheck(TM) ⁰³	3.1	Low		% by wt	>5.4
Relative Risk: HIGH Increasing blood levels of long-chain n-3 fatty acids are associated with a lower risk of sudden cardiac death (1). Based on the top (75th percentile) and bottom (25th percentile) quartiles of the CHL reference population, the following risk categories were established for OmegaCheck: A cut-off of >=5.5% by wt defines a population at low relative risk, 3.8-5.4% by wt defines a population at moderate relative risk, and <=3.7% by wt defines a population at high relative risk of sudden cardiac death. The totality of the scientific evidence demonstrates that when consumption of fish oils is limited to 3 g/day or less of EPA and DHA, there is no significant risk for increased bleeding time beyond the normal range. A daily dosage of 1 gram of EPA and DHA lowers the circulating triglycerides by about 7-10% within 2 to 3 weeks. (Reference: 1-Albert et al. NEJM. 2002; 346: 1113-1118).					
Arachidonic Acid/EPA Ratio ⁰³	26.2				3.7-40.7
Omega-6/Omega-3 Ratio ⁰³	13.6				3.7-14.4
Omega-3 total ⁰³	3.1			% by wt	
EPA ⁰³	0.5			% by wt	0.2-2.3
DPA ⁰³	1.2			% by wt	0.8-1.8
DHA ⁰³	1.4			% by wt	1.4-5.1
Omega-6 total ⁰³	42.0			% by wt	
Cleveland HeartLab measures a number of omega-6 fatty acids with AA and LA being the two most abundant forms reported.					
Arachidonic Acid ⁰³	12.0			% by wt	8.6-15.6
Linoleic Acid ⁰³	26.7			% by wt	18.6-29.5
This test is performed by a Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) method. This test was developed and its performance characteristics determined by the Cleveland HeartLab, Inc. It has not been cleared or approved by the U.S. FDA. The Cleveland HeartLab is regulated under					

Date Collected: 01/20/2025

OmegaCheck(TM) (EPA+DPA+DHA) (Cont.)

Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

PDF ⁰³	.
-------------------	---

Iron and TIBC

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Iron Bind.Cap.(TIBC)	365		ug/dL	250-450
UIBC ⁰²	244		ug/dL	111-343
Iron ⁰²	121		ug/dL	38-169
Iron Saturation	33		%	15-55

Testosterone Free, Profile I

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Testosterone ⁰²	774		ng/dL	264-916
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.				
Sex Horm Binding Glob, Serum ⁰²	53.7		nmol/L	16.5-55.9
Testost., Free, Calc	124.9		pg/mL	30.3-183.2

Albumin/Creatinine Ratio,Urine

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Creatinine, Urine ⁰²	25.5		mg/dL	Not Estab.
Albumin, Urine ⁰²	<3.0		ug/mL	Not Estab.
Alb/Creat Ratio	<12		mg/g creat	0-29
			Normal:	0 - 29
			Moderately increased:	30 - 300
			Severely increased:	>300

ABO Grouping and Rho(D) Typing

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
ABO Grouping ⁰²	A			
Rh Factor ⁰²	Positive			
Please note: Prior records for this patient's ABO / Rh type are not available for additional verification.				

PSA Total (Reflex To Free)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Prostate Specific Ag ⁰²	0.3		ng/mL	0.0-4.0
Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial				

Date Collected: 01/20/2025

PSA Total (Reflex To Free) (Cont.)

PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.
Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Reflex Criteria ⁰²	The percent free PSA is performed on a reflex basis only when the total PSA is between 4.0 and 10.0 ng/mL.			
-------------------------------	--	--	--	--

Hemoglobin A1c

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Hemoglobin A1c ⁰²	5.4		%	4.8-5.6
Please Note: ⁰²	Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0			

Thyroxine (T4) Free, Direct

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
T4,Free(Direct) ⁰²	1.11		ng/dL	0.82-1.77

Folate (Folic Acid), Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Folate (Folic Acid), Serum ⁰²	>20.0		ng/mL	>3.0
Note: ⁰²	A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency.			

DHEA-Sulfate

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
DHEA-Sulfate ⁰²	84.4		ug/dL	71.6-375.4

Cortisol

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Cortisol ⁰²	12.6		ug/dL	6.2-19.4
Please Note: The reference interval and flagging for this test is for an AM collection. If this is a PM collection please use: Cortisol PM: 2.3-11.9				

TSH

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
TSH ⁰²	1.650		uIU/mL	0.450-4.500

Luteinizing Hormone(LH)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LH ⁰²	5.3		mIU/mL	1.7-8.6

Date Collected: 01/20/2025

FSH

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
FSH ⁰²	4.3		mIU/mL	1.5-12.4

Prolactin

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Prolactin ⁰²	14.2		ng/mL	3.9-22.7

Estradiol

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ Estradiol ⁰²	43.0 High		pg/mL	7.6-42.6
Roche ECLIA methodology				

Rheumatoid Factor (RF)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Rheumatoid Factor (RF) ⁰²	<10.0		IU/mL	<14.0

Lead, Blood (Adult)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Lead, Blood (Adult) ^{A, 04}	<1.0		ug/dL	0.0-3.4
Blood Lead Collection Method: Venous Testing performed by Inductively coupled plasma/Mass Spectrometry. Analysis by inductively coupled plasma/mass spectrometry (ICP/MS)				
Environmental Exposure: WHO Recommendation <5.0 Occupational Exposure: OSHA Lead Std 40.0 BEI 30.0 Detection Limit = 1.0				

IGF-1

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Insulin-Like Growth Factor I ⁰⁵	166		ng/mL	84-270

Vitamin D, 25-Hydroxy

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Vitamin D, 25-Hydroxy ⁰²	59.2		ng/mL	30.0-100.0
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice				

Date Collected: 01/20/2025

Vitamin D, 25-Hydroxy (Cont.)

guideline. JCEM. 2011 Jul; 96(7):1911-30.

Lipoprotein (a)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Lipoprotein (a) ⁰¹	24.4		nmol/L	<75.0
Note: Values greater than or equal to 75.0 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities.				

C-Reactive Protein, Cardiac

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ C-Reactive Protein, Cardiac ⁰²	4.38 High		mg/L	0.00-3.00
Relative Risk for Future Cardiovascular Event				
Low			<1.00	
Average			1.00 - 3.00	
High			>3.00	

Leptin, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Leptin, Serum ^{B, 01}	2.0		ng/mL	
Male Ranges by Body Mass Index (BMI)				
BMI		Range	BMI	Range
11	0.1 - 0.4	25	1.1 - 9.6	
12	0.1 - 0.6	26	1.3 - 12.0	
13	0.1 - 0.7	27	1.6 - 14.9	
14	0.1 - 0.9	28	2.0 - 18.6	
15	0.1 - 1.1	29	2.5 - 23.2	
16	0.2 - 1.3	30	3.2 - 28.9	
17	0.2 - 1.7	31	3.9 - 36.0	
18	0.2 - 2.1	32	4.9 - 44.9	
19	0.3 - 2.6	33	6.1 - 55.8	
20	0.4 - 3.2	34	7.6 - 69.6	
21	0.4 - 4.0	35	9.5 - 86.7	
22	0.5 - 5.0	36	11.8 - 108.0	
23	0.8 - 6.2	37	14.8 - 135.0	
24	0.9 - 7.7			
Blum WF, Juul A, "Reference Ranges of Leptin Levels According to Body Mass Index, Gender and Development Stage" in Leptin: The Voice of Adipose Tissue, Blumm WF, Kiess WF, and Rascher W, eds, 1997, 319-326.				

Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Homocyst(e)ine ⁰²	11.1		umol/L	0.0-14.5

Date Collected: 01/20/2025

Uric Acid

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Uric Acid ⁰²	5.0		mg/dL	3.8-8.4
Therapeutic target for gout patients: <6.0				

GGT

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
GGT ⁰²	22		IU/L	0-65

Amylase

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ Amylase ⁰²	115 High		U/L	31-110

Lipase

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Lipase ⁰²	40		U/L	13-78

Vitamin B12

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Vitamin B12 ⁰²	816		pg/mL	232-1245

Magnesium

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Magnesium ⁰²	1.9		mg/dL	1.6-2.3

Zinc, Plasma or Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Zinc, Plasma or Serum ^{A, 04}	81		ug/dL	44-115
			Detection Limit = 5	

Insulin

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▼ Insulin ⁰²	2.4 Low		uIU/mL	2.6-24.9

Ferritin

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Ferritin ⁰²	55		ng/mL	30-400

Triiodothyronine (T3), Free

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Triiodothyronine (T3), Free ⁰²	3.3		pg/mL	2.0-4.4

Date Collected: 01/20/2025

Apolipoprotein B

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Apolipoprotein B ⁰²	87		mg/dL	<90
		Desirable	< 90	
		Borderline High	90 - 99	
		High	100 - 130	
		Very High	>130	

	ASCVD RISK	THERAPEUTIC TARGET		
	CATEGORY	APO B (mg/dL)		
	Very High Risk	<80 (if extreme risk <70)		
	High Risk	<90		
	Moderate Risk	<90		

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Comments
A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
B: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Performing Labs
01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
02: SO - Labcorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 92128-4108 Dir: Earle Collum, Jr, MD
03: CLHRT - Cleveland Heartlab Inc, 6701 Carnegie Avenue Ste 500, Cleveland, OH 44103-4623 Dir: Bill Richendollar, MD
04: SPOWA - Labcorp Spokane, 110 W Cliff Dr. Ste 100-200, Spokane, WA 99204-3614 Dir: Shefali Goyal, MD
05: CETWE - Labcorp Phoenix, 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969 Dir: Earle Collum, MD
For inquiries, the physician may contact Branch: 800-597-8026 Lab: 858-668-3700

Patient Details	Physician Details	Specimen Details
Callahan, Sean		Specimen ID:
		Control ID:
		Alternate Control Number:
		Date Collected: 01/20/2025
Phone:	Phone:	Date Received: 01/21/2025
Date of Birth:	Account Number:	Date Entered: 01/21/2025
Age: 45	Physician ID:	Date Reported: 01/30/2025
Sex: Male	NPI:	
Patient ID:		
Alternate Patient ID:		

Patient Information	Specimen Information	Client Information
CALLAHAN, SEAN <div></div> Gender: Male Fasting: Fasting Phone: <div></div> <div></div>	Order ID: <div></div> Requisition: <div></div> Collected: 01/20/2025, 11:44 AM Received: 01/23/2025, 3:30 PM Reported: 01/29/2025, 09:40 AM	<div></div> <div></div> <div></div> <div></div>

Cardiometabolic Report

Test Name	Current		Reference Range/Relative Risk Categories				Historical	
	Result & Relative Risk		Optimal	Moderate	High	Units	Result & Relative Risk	
	Optimal	Non-Optimal					//	//
FATTY ACIDS								
OmegaCheck® (Whole Blood: EPA+DPA+DHA) ⁽¹⁾		3.1	≥5.5	3.8-5.4	≤3.7	% by wt		
Arachidonic Acid/EPA Ratio	26.2			3.7-40.7				
Omega-6/Omega-3 Ratio	13.6			3.7-14.4				
Omega-3 total	3.1					% by wt		
EPA	0.5			0.2-2.3		% by wt		
DPA	1.2			0.8-1.8		% by wt		
DHA	1.4			1.4-5.1		% by wt		
Omega-6 total	42.0					% by wt		
Arachidonic Acid	12.0			8.6-15.6		% by wt		
Linoleic Acid	26.7			18.6-29.5		% by wt		

UND = UNDETECTABLE

INC = INCOMPUTABLE

Medical Information For Healthcare Providers: If you have any questions about any of the tests in our Cardiometabolic Report, please call Cleveland HeartLab Client Services at 866.358.9828, option 1 to arrange a consult with our clinical education team.

Cardiometabolic Comment Report

FATTY ACIDS									
OmegaCheck® (Whole Blood: EPA+DPA+DHA) ⁽¹⁾								Lab: Z4M	
<p>Increasing blood levels of long-chain n-3 fatty acids are associated with a lower risk of sudden cardiac death (1). Based on the top (75th percentile) and bottom (25th percentile) quartiles of the CHL reference population, the following relative risk categories were established for OmegaCheck: A cut-off of >=5.5% by wt defines a population at optimal relative risk, 3.8-5.4% by wt defines a population at moderate relative risk, and <=3.7% by wt defines a population at high relative risk of sudden cardiac death. The totality of the scientific evidence demonstrates that when consumption of fish oils is limited to 3 g/day or less of EPA and DHA, there is no significant risk for increased bleeding time beyond the normal range. A daily dosage of 1 gram of EPA and DHA lowers the circulating triglycerides by about 7-10% within 2 to 3 weeks. (Reference: 1-Albert et al. NEJM. 2002; 346: 1113-1118).</p>									
Omega-6 total								Lab: Z4M	
Cleveland HeartLab measures a number of omega-6 fatty acids with AA and LA being the two most abundant forms reported.									

Patient Information	Specimen Information	Client Information
CALLAHAN, SEAN [REDACTED] Gender: Male Fasting: Fasting [REDACTED]	Order ID: [REDACTED] Collected: 01/20/2025, 11:44 AM Received: 01/23/2025, 3:30 PM Reported: 01/29/2025, 09:40 AM	[REDACTED]

Footnotes

(1) This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

Z4M CLEVELAND HEARTLAB INC, 6701 CARNEGIE AVENUE SUITE 500, CLEVELAND, OH 44103-4623 Medical Director: Sami Albeiroti, PhD, D(ABCC) CLIA:36D1032987